WHO ICTRP trial
PHASE 1B/2 STUDY OF ITU V937 IN COMBINATION WITH PEMBROLIZUMAB
PER-066-20 · Registro Peruano de Ensayos Clínicos (REPEC) · Not Recruiting
Key facts
| Trial ID | PER-066-20 |
|---|---|
| Public title | PHASE 1B/2 STUDY OF ITU V937 IN COMBINATION WITH PEMBROLIZUMAB |
| Scientific title | A PHASE 1B/2 CLINICAL STUDY OF INTRATUMORAL ADMINISTRATION OF V937 IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) IN PARTICIPANTS WITH ADVANCED/METASTATIC SOLID TUMORS |
| Primary sponsor | Merck Sharp & Dohme Corp., una subsidiaria de Merck & Co. Inc., |
| Registry | Registro Peruano de Ensayos Clínicos (REPEC) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | II |
| Countries | Israel;Japan;Taiwan;Germany;Spain;France;Hungary;Norway;United Kindgdom;Russian Federation;Brazil;Canada;Colombia;Peru;United States |
| Conditions | -C97 Malignant neoplasms of independent (primary) multiple sites Malignant neoplasms of independent (primary) multiple sites;C97 |
| Interventions | Group name:Arm 1 Type of group;1 N° of participants:2 Intervention(s) description:V937 Dosis:3 × 108 TCID50 Frecuency: Cycle 1, days 1, 3, 5 y 8 (4 dosis) luego cada 3 semanas Pembrolizumab Dosis: 200mg Frecuency: Every 3 weeks Group… |
| Registration date | Oct 22, 2020 |
| Target size | 6 |
| Secondary IDs | 2020 001908 42 |
| Registry page | ins.gob.pe |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: